MedTrace Logo

Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies

NCT00721903 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2016-05-05

No results posted yet for this study

Summary

The purpose of this study is to determine how well changes can be determined in malignant masses from ultrasound scans.

Conditions

Interventions

PROCEDURE

Ultrasound Scan

10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.

PROCEDURE

Mammography and Ultrasound

To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Michigan

    lead OTHER

Principal Investigators

  • Paul L. Carson, Ph.D. · University of Michigan

  • Paul Carson, PhD · University of Michigan

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-03-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00721903 on ClinicalTrials.gov